µ²ºc¦¡ |
|
Omeprazole 6-methoxy-2-((4-methoxy-3,5-dimethylpyridin-2-yl) methylsulfinyl)-1H-benzo[d]imidazole
|
UpToDate |
UpToDate ³sµ²
|
ÃIJz§@¥Î |
|
Omezol(Omeprazole)ÂǥѤ@°ª«×¥Ø¼Ð¤Æ¤§¾÷Âà¨Ó´î¤ÖG»Ä¤§¤Àªc¡C¨ä¨³³t²£¥Í§@¥Î¡A¨Ã¸g¥Ñ¨C¤éµ¹ÃĤ@¦¸¤§¾÷¨î¡A¥i°f©Ê¦a§í¨îG»Ä¤§¤Àªc¡CƒÜ Omezol(Omeprazole)¬°¤@®zÆP¡A¨ä·|¦bG¤§¾À²ÓM¤º¤§²ÓM¤º¤pºÞ¡A¶°¤¤¨ÃÂà¤Æ¦¨¬¡©Ê«¬¡A¨ä¥i§í¨î»ÄÀ°®ú:H+-K+-ATP»Ã¯À¡C¨ä®ÄÀ³¨ã¾¯¶q¨Ì¿à©Ê¡A¥B¹ï°ò¦¤§G»Ä¤Àªc¤Î¨ë¿E¤U¤§G»Ä¤Àªc(µL½×¦óºØ¨ë¿E)¡A§¡¦³±j¯P¤§§í¨î®ÄªG¡CƒÜ Omezol¨C¤Ñ¤fªA¤@¦¸¡A¯à¨³³t¤Î¦³®Äªº§í¨î¥Õ¤Ñ¤Î©]¶¡¤§G»Ä¤Àªc¡A¦bªvÀø4¤Ñ«á¹F¨ì¨ä³Ì¤jÀø®Ä¡CƒÜ ¤Q¤G«ü¸z¼ìºÅ±wªÌªA¥ÎOmezol 20mg«á¡A¦bµ¹ÃÄ«á24¤p®É´Á¶¡¡A¥§¡¦³17¤p®É¨äG¤º¤§»ÄÆP«×¡Ö3¡CƒÜ ¦]¬°G»Ä¤Àªc¤ÎG¤º»Ä«×°§C¤§µ²ªG¡AOmeprazole¨Ì¾¯¶q¤§¦h¹è¡A¥i¨ÏG-¹¹D°f¬y±wªÌ¤§¹¹D¡A¯à¼ÉÅS©ó¥¿±`©Î»Ä«×¸û§C¤§G»Ä¡C¹ï»Ä¤Àªc¤§§í¨î¡A»P¦å¼ßOmeprazole¿@«×»P®É¶¡¡A©Ò§Î¦¨¤§¦±½u¤U±¿n¡]AUC¡^¦³¬ÛÃö©Ê¡A¦ý»Pµ¹ÃÄ«á¦å¼ß¯u¥¿¤§¿@«×«oµL¬ÛÃö¡C¥HOmeprazoleªvÀø¤§´Á¶¡¡A¨Ã¤£·|²£¥ÍÀø®Ä§Ö³t°§C¤§²{¶H
|
¾AÀ³¯g |
|
¤Q¤G«ü¸z¼ìºÅ¡BG¼ìºÅ¡B°f¬y©Ê¹¹Dª¢¡BZollinger - Ellison¯gÔ¸s¡B¦X¨Ö§Ü¥Í¯ÀªvÀø»P«ÕªùÁ³±Û±ìµß¬ÛÃöªº®ø¤Æ©Ê¼ìºÅ¡C
|
¥Îªk¥Î¶q |
|
G¼ìºÅ¡G«Øij¾¯¶q¬°Omezol 20mg¡A¨C¤Ñ¤@¦¸¡C¯gª¬¥i¨³³t½w¸Ñ¡A¥B¤j¦h¼Æ±wªÌ·|¦b4¶g¤º²¬Â¡¡C ¤Q¤G«ü¸z¼ìºÅ¡G¹ï±w¦³¬¡°Ê©Ê¤Q¤G«ü¸z¼ìºÅ¤§¯f¤H«Øij¾¯¶q¬°Omezol 20mg¡A ¨C¤Ñ¤@¦¸¡C °f¬y©Ê¹¹Dª¢¡G«Øij¾¯¶q¬°Omezol 20mg¡A¨C¤Ñ¤@¦¸¡A¯gª¬¥i¨³³t½w¸Ñ¡A¥B¤j¦h¼Æ±wªÌ·|¦b4¶g¤º²¬Â¡¡C Zollinger-Ellison¯gÔ¸s¡GªvÀøZollinger-Ellison¯gÔ¸s¤§¾¯¶q»Ý¨ÌÓ¤H¨Ó½Õ¾ã¡A¥B¥unÁ{§É¤W»Ýn¡A´N«ùÄòªvÀø¤U¥h¡C«Øij¾¯¶q¬°¨C¤ÑOmezol 6Omg¡C
|
°Æ§@¥Î |
|
ÀYµh¡AG¸z¹Dªº¼vÅT¡C
|
¸T§Ò |
|
¤wª¾¹ïOmeprazole·|µo¥Í¹L±Ó¤ÏÀ³ªÌ¡C
|
µ¹¥I³W©w |
|
7.1.®ø¤Æ©Ê¼ìºÅ¥ÎÃÄ¡G 1.ÃÄ«~ºØÃþ¡G ²BÂ÷¤lÀ°®úªýÂ_¾¯¡G ¦U¼tµP²BÂ÷¤lÀ°®úªýÂ_¾¯¡C 2.¨Ï¥Î³W©w¡G(106/12/1¡B110/12/1) (1)¨Ï¥Î©óªvÀø¬¡°Ê©Ê¡]active¡^©Î¡¦X¤¤¡]healing¡^¤§®ø¤Æ©Ê¼ìºÅ¤Î°f¬y©Ê¹¹Dª¢¡C(92/10/1) (2)½I²ª´Á¡]scar stage¡^¤§®ø¤Æ©Ê¼ìºÅ´_µo¹w¨¾¡A¨ä¾¯¶q¨Ì·ÓÂå²z´î¶q¨Ï¥Î¡C (3)®ø¤Æ©Ê¼ìºÅ¤Î°f¬y©Ê¹¹Dª¢²Å¦X¬¥§üÁF¹¹Dª¢¤À¯Åªí¡]The Los Angeles Classification of Esophagitis¡°³Æµù¡^Grade A©ÎGrade BªÌ¡A±ý¨Ï¥Î®ø¤Æ©Ê¼ìºÅ¥ÎÃÄ¡A¨ä¨Ï¥Î´Á¶¡¥H¥|Ӥ묰¡A¥Ó³ø¶O¥Î®É»ÝÀ˪þ¥|Ӥ뤺¦³®Ä¤§¤W®ø¤Æ¹D¤ºµøÃèÀˬd©Î¤W®ø¤Æ¹D¢æ¥úÄá¼v³ø§i¡A¨ä°w¾¯¨Ï¥Î©ó®ø¤Æ¹D¥X¦å¤£¯à¤fªA¤§¯f¤H«æ©Ê´Á´À¥NÀøªk¡C(92/10/1) (4)¸g¤W®ø¤Æ¹D¤ºµøÃèÀˬd¡A¶EÂ_¬°««×°f¬y©Ê¹¹Dª¢¡A¥B²Å¦X¬¥§üÁF¹¹Dª¢¤À¯Åªí¡]The Los Angeles Classification of Esophagitis¡°³Æµù¡^Grade C©ÎGrade DªÌ¡A±o¸g®ø¤Æ¨t±M¬ìÂå®v¤§½T»{«á¥iªø´Á¨Ï¥Î®ø¤Æ©Ê¼ìºÅ¥ÎÃĤ@¦~¡C¥t¥~¡A¤U¦C¯f±w±o¤ñ·Ó¿ì²z¡G(92/10/1) ¢¹.G¤Á°£¤â³NÁ_±µ³B²£¥Í¤§¼ìºÅ¡C ¢º.¸g®ø¤Æ¨t±M¬ìÂå®v«ÂЦh¦¸¡]¤T¦¸¥H¤W¡^¤W®ø¤Æ¹D¤ºµøÃèÀˬd½T»{ÄÝÃøªv¡©Ê¤§¼ìºÅ¡C¸g¶EÂ_½T©w¬°Zollinger-Ellision¯gÔ¸s¤§¯f±w¡A±oªø´Á¨Ï¥Î²BÂ÷¤lÀ°®úªýÂ_¾¯¦Ó¤£¨ü¤@¦~¤§¨î¡C (5)¦]¸£¤¤·¡A«aª¬°Ê¯ß¯e¯f©Î©PÃä¦åºÞ¯e¯f¡A©Î©ö¥X¦åÅé½è(³Æµù)¦Ó»Ý¨Ï¥ÎÂù«§Ü¦å¤pªOÃĪ«¤Î§Ü¾®¦åÃĪ«¡A¦paspirin¡Bwarfarin¡Btirofiban¡Bcilostazol¡B P2Y12 inhibitor¡]¦pclopidogrel¡Bticagrelor¡Bticlopidine¡Bprasugrel¡^©Î·s¤@¥N¤fªA§Ü¾®¦åÃĪ«¡]¦privaroxaban¡Bapixaban¡Bedoxaban¡Bdabigatran¡^¯f¤H±o¥H¨Ï¥Î¨C¤éÃĶO6.5¤¸¥H¤U¤§²BÂ÷¤lÀ°®úªýÂ_¾¯(PPI)¡A³Ìªø¥H16¶g¬°¡FY¬°´¿±µ¨ü¹L¤ºµøÃèÀˬd¡A¸g±m¦â¤ºµøÃè¹ÏÃÐÃҹ꦳¬¡°Ê©Ê®ø¤Æ©Ê¼ìºÅ©Î¤W®ø¤Æ¹D¥X¦å¡A³Ìªø¥H¤@¦~¬°¡A¦p¨Ï¥Î´Á¶¡©Î°±ÃÄ«á¡A¬¡°Ê©Ê®ø¤Æ©Ê¼ìºÅ¦Aµo©Î¤W®ø¤Æ¹D¥X¦å¡A±o¦AªvÀø¤@¦~¡C(110/12/1) ³Æµù¡G©ö¥X¦å©ÊÅé½è«Øij¦p¤U(110/12/1)¡G I. ²Ä¤´ÁºC©ÊµÇŦ¯f(eGFR<15mL/min/1.73M2)©Î³zªRªvªvÀø¤¤ II. ¦å¤pªO¡Õ80,000 /mm3¡C III. ¨xŦ¯e¯f¥BINR>1.7¡C IV. ¨ä¥L¾®¦å¥\¯à¤£¥þ¯e¯f¡C (6)»Ý¨Ï¥ÎNSAIDs¦Ó´¿¸g¤W®ø¤Æ¹D¤ºµøÃè©Î¢æ¥úÄá¼vÃҹ꦳¹L¼ìºÅ¡A±o©ó¨Ï¥ÎNSAIDs´Á¶¡¤º¡A¸g®ø¤Æ¨t±M¬ìÂå®v¤§½T»{«á¥i¨Ï¥Î®ø¤Æ©Ê¼ìºÅ¥ÎÃÄ¡C(92/10/1¡B110/12/1) (7)¹ï©ó¯gª¬ÀÀ¦ü°f¬y©Ê¹¹Dª¢¤§±wªÌ¡A¦ý¨ä¤W®ø¤Æ¹D¤ºµøÃèÀˬdµL²§±`¡AY±ý¨Ï¥Î®ø¤Æ©Ê¼ìºÅ¥ÎÃÄ¡A«h»ÝÀ˪þ¨ä¥L¬ÛÃöÀˬd¡]¦p24¤p®ÉpHºÊ´ú¡^ªºµ²ªG¡C(92/10/1) (8)®ø¤Æ©Ê¼ìºÅ¬ï¤Õ¯f¤H¸g¤â³NÃÒ¹êªÌ¡A¥B©Ò¬I¤â³N¶È¬°³æ¯ÂÁ_¦X¡A¥¼§@G»Ä§í¨î¬ÛÃö¤â³NªÌ¡A¥iÀ˪þ¤â³N°O¿ý©Î¯f²zÀËÅç³ø§i¡A¥Ó½Ð¨Ï¥Î®ø¤Æ©Ê¼ìºÅ¥ÎÃÄ¡A¦ý¥H¥|Ӥ뤺¬°¡A¦p»ÝÄ~Äò¨Ï¥Î¡A¤´½ÐÀ˪þGÃèÀˬd©Î¤W¸zG¹D¢æ¥úÀˬd¥|Ӥ뤺¦³®Ä³ø§i¼v¥»¡C(92/10/1) (9)ÄY«¥~¶Ë¡B¤j¤â³N¡B¸£¤â³N¡BÄY«¿S¶Ë¡B¥ð§J¡BÄY«¯ØŦª¢¤Î«æ©Ê¸£¤¤·ªÌ¬°¹w¨¾À£¤O©Ê¼ìºÅ¡A±o¨Ï¥Î®ø¤Æ©Ê¼ìºÅÃÄ«~¡C¦¹ÃþÃĪ«¤§°w¾¯¨Ï¥Î©ó¤£¯à¤fªA¤§«ez¯f±wµu´Á´À¥NÀøªk¡C (10)®ø¤Æ©Ê¼ìºÅ¯f±w±o¶i¦æªì¦¸«ÕªùÁ³±Û±ìµß®ø°£ªvÀø¡A¨Ï¥Î®É»ÝÀ˪þ¤W®ø¤Æ¹D¤ºµøÃèÀˬd©Î¤W®ø¤Æ¹D¢æ¥úÄá¼v³ø§i¨Ãµù©úªì¦¸ªvÀø¡C(92/10/1) (11)«ÕªùÁ³±Û±ìµß¤§®ø°£ªvÀøÀøµ{¥H¤G¶g¬°ì«h¡A¯S®í¯f¨Ò»Ý©µªøªvÀø©Î¦A¦¸ªvÀø¡A»ÝÀ˪þ¬ÛÃöÀËÅç³ø§i»¡©ú²z¥Ñ¡C (12)¤U¦C¯f±wY¦]ªø´ÁªA¥ÎNSAIDs¦Ó»Ý¨Ï¥Î«e¦C¸¢¯À¾¯(¦pmisoprostol)¡A±o§KªþGÃè³ø§i¡G(99/7/1) ¢¹¬õ´³©Ê¯T½H¡C ¢º¤¤Q·³¥H¤W¿©±wÃþ·Àã©ÊÃö¸`ª¢©Î»øª½©Ê¯á´Õª¢¤§¯f±w¡C (13)¸g®ø¤Æ¨t±M¬ìÂå®v¤W®ø¤Æ¹D¤ºµøÃèÀˬd¡A¨Ã¸g¯f²z¤Á¤ù½T¶E¬°Barrett¡¦s esophagus¤§¯f±w¡A¥i¨Ï¥Î®ø¤Æ©Ê¼ìºÅ¥ÎÃĤ@¦~¡A¤@¦~¤º¦Ü¤Ö¶·¸g¤W®ø¤Æ¹D¤ºµøÃèÀˬd°lÂܤ@¦¸¡C(101/1/1) (14)¸£©Ê³Â·ô¡B¥ý¤Ñ©Ê¤ßŦ¯f¡B®ø¤Æ¹D·î§Î¤Î¨ä¥L¦³¬I¦æGÃèÀˬd§xÃø¤§¨à¬ì¯f±w¦³®ø¤Æ¹D¥X¦å¡B®ø¤Æ©Ê¼ìºÅ¡B°f¬y©Ê¹¹Dª¢ªÌ¡A¥i¨Ï¥Î®ø¤Æ©Ê¼ìºÅ¥ÎÃĤ»Ó¤ë¡C¤Wz¯f¤HY¸g¤W®ø¤Æ¹DX¥úÄá¼v©Î¸g¹¹D»ÄÆP«×´ú©w¬°««×°f¬yªÌ¡A±o¸g¨à¬ì®ø¤ÆÂå¾Ç¦¸±M¬ìÂå®v½T»{«áªø´Á¨Ï¥Î®ø¤Æ©Ê¼ìºÅ¥ÎÃĤ@¦~¡C(106/12/1) ³Æµù¡G 1.The Los Angeles Classification of Esophagitis Grade A: One or more mucosal break,each ¡Ø5mm long,confined to the mucosal folds¡C Grade B: One or more mucosal break > 5mm long, confined to the mucosal folds but not continuous between the tops of two mucosal folds¡C Grade C: One or more mucosal break continuous between the tops of two or more mucosal folds but which involve less than 75% of the esophageal circumference¡C Grade D: Mucosal breaks which involve less than 75% of the esophageal circumference¡C 2. ÂåÀø°|©Ò¨Ï¥Î³æ»ù·s¥x¹ô¥|¤¸(§t)¥H¤U¤§®ø¤Æ©Ê¼ìºÅ¥ÎÃĮɡA±o¥ÑÂå®vµø¯f±¡¨M©w¬O§_»Ýn¤W®ø¤Æ¹D¤ºµøÃèÀˬd¡C(92/10/1)
|
ĵ»y |
|
·íÃhºÃ¬OG¼ìºÅ¤§®É¡AÀ³¥ý½T»{¨ä¨Ã«D´c©Ê¸~½F¡A¦]¥»ªvÀø¥i¯à·|´î»´¨ä¯gª¬¡A¨Ã©µ»~¨ä¶EÂ_¡C
|
¹L¶q³B²z |
|
³æ¦¸¤fªA400 mg¤§Omezol½¦Ån¨Ã¤£¾ÉP¥ô¦óÄY«¤§¯gª¬¡CÀHµÛ¾¯¶q¤§¼W¥[¡A¨ä±Æ°£³t²v¤´µMºû«ù¤£ÅÜ(¤@¶¥°Ê¤O¾Ç)¡A¥B¤£¶·¥ô¦ó¯S®íªvÀø¡C
|
ÃÄ«~«O¦s¤è¦¡ |
|
¶J¦s©ó§C©ó30¢J³B¡C
|